Sign up to get the latest stories and insights delivered to your inbox – free, every day.
The Auckland High Court has upheld the guilty finding and sentence of Tony Gibson, after the former Port of Auckland chief executive was held liable in November 2024 for the death of stevedore, Pala'amo Kalati, four years earlier. Maritime NZ had prosecuted Gibson – the CEO of the port for 10 years prior – under section 48 of the Health and Safety at Work Act and he was found to have failed to exercise due diligence to ensure the port complied with its primary duty of care to ensure the health and safety of its workers. The District Court had fined Gibson $130,000 and ordered him to pay costs of $60,000. The 2020 death had been the fourth fatality at the terminal in as many years, and netted the council-owned operator a fine of $561,000. It also paid separate reparations to Kalati's family.
Kiwi biotech company BioOra has confirmed a strategic partnership with Cincinnati Children’s Hospital (CCH) for using its next-generation Car-T cell therapy for children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukaemia.
As part of the deal, CCH chief executive Steve Davis will join BioOra’s board. CCH already holds a 10% stake in the company.
BioOra’s novel chimeric antigen receptor therapy, Alta-Cel, reprogrammes a patient’s own immune cells to locate and destroy cancer cells. Its New Zealand Enable trials for adult patients with B-cell lymphoma have shown fewer side-effects than existing therapies from cytokine release syndrome and immune-affected neurotoxicity (icans)
In children, icans is not a side effect to be managed, it is an unacceptable risk, the partners said.
Stella Davies, who will lead the trial for CCH, said the low neurotoxicity signals from the Enable programme make Alta-cel a compelling candidate for paediatric investigation.